Storyline
Lilly warns of dangerous impurities in tirzepatide knockoff compounds
Eli Lilly has raised concerns about high levels of impurities found in compounded versions of tirzepatide, a GLP-1 receptor agonist used for obesity treatment. The company warns that these knockoff formulations, some combined with vitamin B12, may pose safety risks to patients.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- BioPharmaDive report on Lilly's impurity warningsbiopharmadive.com
- FiercePharma coverage of Lilly's compounding disputefiercepharma.com